IPP-204106 is under clinical development by Immupharma and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IPP-204106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IPP-204106 overview

IPP-204106 is under development for the treatment of advanced solid tumors including metastatic breast cancer, metastatic lung cancer, pancreatic cancer, age-related macular degeneration, metastatic bladder cancer. The drug candidate is administered by the intravenous route. IPP-204106 has a dual mechanism of action, acts by targeting nucleolin/nucleophosmin. It is developed based on the peptide to drug converting technology. The drug candidate was also under development for the treatment of colon cancer, leukemias, melanoma, prostate cancer, and glioblastoma multiforme.

Immupharma overview

Immupharma biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. Immupharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; BioCIN, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and P140, a drug developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. It has operations in France and Switzerland. Immupharma is headquartered in London, Greater London, the UK.

For a complete picture of IPP-204106’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.